Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 Next >
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Provides Corporate Update on Upcoming Clinical Milestones
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Completion of Previously Announced Share Consolidation
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate at the 27th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
From Cybin Inc.
Via Business Wire
Tickers CYBN
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.